Oxford BioDynamics Plc (LON:OBD – Get Free Report)’s stock price rose 20% during mid-day trading on Wednesday. The stock traded as high as GBX 0.12 and last traded at GBX 0.12. 150,116,031 shares were traded during mid-day trading, an increase of 534% from the average daily volume of 23,669,771 shares. The stock had previously closed at GBX 0.10.
Oxford BioDynamics Stock Up 20.0%
The company has a debt-to-equity ratio of 131.61, a quick ratio of 2.80 and a current ratio of 2.01. The company has a market capitalization of £16.13 million, a PE ratio of -0.60 and a beta of 0.42. The firm’s 50-day simple moving average is GBX 0.12 and its 200 day simple moving average is GBX 0.15.
Oxford BioDynamics Company Profile
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
Read More
- Five stocks we like better than Oxford BioDynamics
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
